Microarray technology to investigate genes associated with papillary thyroid carcinoma

Zhu,Xinyong; Yao,Jing; Tian,Wen

doi:10.3892/mmr.2015.3180

Microarray technology to investigate genes associated with papillary thyroid carcinoma

Authors:
- Xinyong Zhu
- Jing Yao
- Wen Tian
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, The First Hospital Affiliated to General Hospital of PLA, Beijing 100048, P.R. China
Published online on: January 9, 2015 https://doi.org/10.3892/mmr.2015.3180
Pages: 3729-3733

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

DNA microarray data on thyroid tissue from patients with papillary thyroid carcinoma (PTC) and from healthy controls were compared in order to investigate the regulatory genes and uncover the underlying regulatory network in PTC. The DNA microarray data set, GSE3678, was downloaded from Gene Expression Omnibus database. This included seven thyroid tissue samples from patients with PTC and seven samples from healthy controls. Raw data were processed and differentially expressed genes (DEGs) were identified using corresponding R packages. Gene regulation analysis was conducted using TRANSFAC® and TRED. A total of 171 DEGs were obtained. A regulatory network was then established, using 104 of the DEGs. Subsequently, pathway enrichment analyses of the genes were conducted using Database for Annotation, Visualization and Integrated Discovery (DAVID) online tool. Three differentially expressed transcription factors were identified: Trefoil factor 3, cut‑like homeobox 2 and forkhead box protein A2. The most significant pathways involving the 104 DEGs were pathways involved in cancer. Biological process analysis using DAVID, suggested that these genes were associated with the positive regulation of gene expression, gene transcription and metabolic processes. The present study identified a range of genes associated with the development of PTC. The results of the present study were beneficial for understanding the regulatory mechanisms involved in PTC, and for developing clinical diagnostic and therapeutic approaches for this disease.

View Figures

View References

1	Kitamura Y, Minobe K, Nakata T, et al: Ret/PTC3 is the most frequent form of gene rearrangement in papillary thyroid carcinomas in Japan. J Hum Genet. 44:96–102. 1999. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin. 54:8–29. 2004. View Article : Google Scholar : PubMed/NCBI
3	Lang BH, Chow SM, Lo CY, et al: Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers. Ann Surg. 246:114–121. 2007. View Article : Google Scholar : PubMed/NCBI
4	Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
5	Melillo RM, Castellone MD, Guarino V, et al: The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest. 115:1068–1081. 2005. View Article : Google Scholar : PubMed/NCBI
6	Cohen Y, Xing M, Mambo E, et al: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 95:625–627. 2003. View Article : Google Scholar : PubMed/NCBI
7	Fusco A, Viglietto G and Santoro M: A new mechanism of BRAF activation in human thyroid papillary carcinomas. J Clin Invest. 115:20–23. 2005. View Article : Google Scholar : PubMed/NCBI
8	Nikiforova MN, Kimura ET, Gandhi M, et al: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 88:5399–5404. 2003. View Article : Google Scholar : PubMed/NCBI
9	Jhiang SM, Sagartz JE, Tong Q, et al: Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology. 137:375–378. 1996.PubMed/NCBI
10	Tallini G, Santoro M, Helie M, et al: RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res. 4:287–294. 1998.PubMed/NCBI
11	Ciledag N, Arda K, Aribas BK, Aktas E and Köse SK: The utility of ultrasound elastography and MicroPure imaging in the differentiation of benign and malignant thyroid nodules. AJR Am J Roentgenol. 198:W244–W249. 2012. View Article : Google Scholar : PubMed/NCBI
12	Giordano TJ, Kuick R, Thomas DG, et al: Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 24:6646–6656. 2005. View Article : Google Scholar : PubMed/NCBI
13	Jarzab B, Wiench M, Fujarewicz K, et al: Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 65:1587–1597. 2005. View Article : Google Scholar : PubMed/NCBI
14	Prasad ML, Pellegata NS, Kloos RT, Barbacioru C, Huang Y and de la Chapelle A: CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study. Thyroid. 14:169–175. 2004. View Article : Google Scholar : PubMed/NCBI
15	Vasko V, Espinosa AV, Scouten W, et al: Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA. 104:2803–2808. 2007. View Article : Google Scholar : PubMed/NCBI
16	He H, Jazdzewski K, Li W, et al: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA. 102:19075–19080. 2005. View Article : Google Scholar : PubMed/NCBI
17	Smyth GK: Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor. Gentleman R, et al: Springer; New York: pp. 397–420. 2005, View Article : Google Scholar
18	Benjamini Y and Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 57:289–300. 1995.
19	Wingender E, Kel AE, Kel OV, et al: TRANSFAC, TRRD and COMPEL: towards a federated database system on transcriptional regulation. Nucleic Acids Res. 25:265–268. 1997. View Article : Google Scholar : PubMed/NCBI
20	Smoot ME, Ono K, Ruscheinski J, Wang PL and Ideker T: Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar :
21	Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
22	Huang Y, Prasad M, Lemon WJ, et al: Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 98:15044–15049. 2001. View Article : Google Scholar : PubMed/NCBI
23	Hawthorn L, Stein L, Varma R, Wiseman S, Loree T and Tan D: TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma. Head Neck. 26:1069–1083. 2004. View Article : Google Scholar : PubMed/NCBI
24	Finley DJ, Arora N, Zhu B, Gallagher L and Fahey TJ III: Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab. 89:3214–3223. 2004. View Article : Google Scholar : PubMed/NCBI
25	Takano T, Miyauchi A, Yoshida H, Kuma K and Amino N: High-throughput differential screening of mRNAs by serial analysis of gene expression: decreased expression of trefoil factor 3 mRNA in thyroid follicular carcinomas. Br J Cancer. 90:1600–1605. 2004. View Article : Google Scholar : PubMed/NCBI
26	Qin XQ, Beckham C, Brown JL, et al: Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol Ther. 4:356–364. 2001. View Article : Google Scholar : PubMed/NCBI
27	Mccarthy N: Tumorigenesis: Cut here for differentiation. Nat Rev Cancer. 12:3202012. View Article : Google Scholar : PubMed/NCBI
28	Arden KC: Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer. Exp Gerontol. 41:709–717. 2006. View Article : Google Scholar : PubMed/NCBI
29	Reagan-Shaw S and Ahmad N: The role of Forkhead-box Class O (FoxO) transcription factors in cancer: a target for the management of cancer. Toxicol Appl Pharmacol. 224:360–368. 2007. View Article : Google Scholar : PubMed/NCBI
30	Nucera C, Eeckhoute J, Finn S, et al: FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res. 15:3680–3689. 2009. View Article : Google Scholar : PubMed/NCBI
31	Kim HS, Kim Do H, Kim JY, et al: Microarray analysis of papillary thyroid cancers in Korean. Korean J Intern Med. 25:399–407. 2010. View Article : Google Scholar : PubMed/NCBI
32	Akagi T, Luong QT, Gui D, et al: Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells. Br J Cancer. 99:781–788. 2008. View Article : Google Scholar : PubMed/NCBI
33	Yashiro T, Arai M, Shizume K, et al: Increased activity of insulin-like growth factor-binding protein in human thyroid papillary cancer tissue. Jpn J Cancer Res. 85:46–52. 1994. View Article : Google Scholar : PubMed/NCBI
34	Soikkeli J, Podlasz P, Yin M, et al: Metastatic outgrowth encompasses COL-I, FN1, and POSTN upregulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth. Am J Pathol. 177:387–403. 2010. View Article : Google Scholar : PubMed/NCBI
35	Takano T, Matsuzuka F, Sumizaki H, Kuma K and Amino N: Rapid detection of specific messenger RNAs in thyroid carcinomas by reverse transcription-PCR with degenerate primers: specific expression of oncofetal fibronectin messenger RNA in papillary carcinoma. Cancer Res. 57:3792–3797. 1997.PubMed/NCBI
36	Soto JL, Cabrera CM, Serrano S and López-Nevot MA: Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B. BMC Cancer. 5:362005. View Article : Google Scholar : PubMed/NCBI
37	Arnaldi LA, Borra RC, Maciel RM and Cerutti JM: Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid. 15:210–221. 2005. View Article : Google Scholar : PubMed/NCBI
38	Kroll TG, Sarraf P, Pecciarini L, et al: PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 289:1357–1360. 2000. View Article : Google Scholar : PubMed/NCBI
39	Antico Arciuch VG, Russo MA, Dima M, et al: Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget. 2:1109–1126. 2011.PubMed/NCBI